Compelling and statistically significant data for 1st line HNSC (TACTI-003) or/and 1st line NSCLC (TACTI-002).
Efficacy - Must be at least good as chemo/Keytruda SOC. Duration of response must be better and less toxic (the latter is a given)
TACTI-Mel may be revisited but probably not until above is completed and Merck have made a play.
JPMorgan conference, page-18
-
- There are more pages in this discussion • 1 more message in this thread...
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)
Add IMM (ASX) to my watchlist
 (20min delay)
|
|||||
|
Last
34.0¢ |
Change
0.005(1.49%) |
Mkt cap ! $493.8M | |||
| Open | High | Low | Value | Volume |
| 34.0¢ | 34.5¢ | 32.8¢ | $839.2K | 2.469M |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 5 | 125437 | 34.0¢ |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| 34.5¢ | 85415 | 6 |
View Market Depth
| Last trade - 16.10pm 15/08/2024 (20 minute delay) ? |
| IMM (ASX) Chart |